Methods of manufacture of therapeutic products comprising vitalized placental dispersions

Patent metadata

Field	Value
Publication number	US-10646519-B2
Application number	US-201815949808-A
Country	US
Kind code	B2
Filing date	Apr 10, 2018
Priority date	Feb 18, 2010
Publication date	May 12, 2020
Grant date	May 12, 2020

Abstract

This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

First claim

What is claimed is:

1. A method of manufacturing a therapeutic placental product comprising:
(a) obtaining a first placental tissue;
(b) isolating placental cells from the first placental tissue;
(c) obtaining a second placental tissue;
(d) homogenizing the second placental tissue to form a homogenous placental dispersion comprising placental factors; and
(e) combining the placental cells and the homogenous placental dispersion to form the placental product.

2. The method of claim 1 , wherein the first placental tissue is autologous to the second placental tissue and wherein the first placental tissue and the second placental tissue are chorionic tissue.

3. The method of claim 2 , wherein the second placental tissue is derived from the first placental tissue after the step of isolating the placental cells.

4. The method of claim 3 , wherein the step of isolating the placental cells comprises exposing the first placental tissue to a protease, optionally wherein the protease is a collagenase.

5. The method of claim 4 , wherein the protease exposing step has a duration of about 30 minutes or less.

6. The method of claim 4 , wherein the protease exposing step releases less than about 10% of the maximum number of releasable placental cells.

7. The method of claim 2 , wherein the chorionic tissue is depleted of trophoblasts.

8. The method of claim 7 , wherein the trophoblasts are depleted by dissection and dispase treatment.

9. The method of claim 1 , wherein the placental product comprises one or more members selected from the group consisting of extracellular matrix proteins; protease inhibitors; angiogenic factors; and placental factors which promotes the migration of epithelial cells into a wound.

10. The method of claim 1 , wherein the placental product comprises one or more protease inhibitors selected from the group consisting of matrix metalloproteinases (TIMPs), alpha-2 macroglobulin, and thrombospondins.

11. The method of claim 1 , wherein the placental product comprises one or more angiogenic factors selected from the group consisting of VEGF and bFGF.

12. The method of claim 1 , wherein the placental product comprises one or more factors which promote the migration of epithelial cells into a wound selected from the group consisting of HGF and KGF.

13. The method of claim 1 , wherein the placental cells are selected from the group consisting of MSCs, ESCs, placenta-derived mesenchymal progenitor cells, placental mesenchymal stem cells, fibroblasts, epithelial cells, placental mesenchymal cells, and macrophages.

14. The method of claim 13 , wherein the placental cells are present at a concentration of at least about 20,000 per ml of placental product.

15. The method of claim 1 , wherein at least one of the placental cells or the placental dispersion is cryopreserved.

16. The method of claim 1 , wherein the placental cells are cryopreserved before combining with the placental dispersion, and wherein the placental dispersion is optionally cryopreserved before combining with the placental cells.

17. The method of claim 1 , wherein the placental cells comprise stromal cells and the placental cells are cryopreserved.

18. The method of claim 3 , wherein:
(a) the step of isolating the placental cells comprises exposing the first placental tissue to a protease;
(b) the protease exposing step is of about 30 minutes or less duration;
(c) the protease exposing step releases less than about 10% of the maximum number of releasable placental cells;
(d) the chorionic tissue is depleted of trophoblasts;
(e) the placental product comprises one or more protease inhibitors selected from the group consisting of matrix metalloproteinases (TIMPs), alpha-2 macroglobulin, and thrombospondins;
(f) the placental product comprises one or more of VEGF and bFGF;
(g) the placental product comprises one or more of HGF and KGF;
(h) the placental cells comprise MSCs and cells selected from the group consisting of ESCs, placenta-derived mesenchymal progenitor cells, placental mesenchymal stem cells, fibroblasts, epithelial cells, placental mesenchymal cells, and macrophages;
(i) the placental cells are present at a concentration of at least about 20,000 per ml of placental product; and
(j) at least one of the placental cells and the placental dispersion is cryopreserved.

19. A method of treating a tissue injury comprising administering to a subject in need thereof a therapeutic placental product made by the method of claim 1 .

Assignees

• Osiris Therapeutics Inc

Inventors

• Tom Samson
• Danilkovitch Alla
• Yoo Dana
• Jansen Timothy
• Kuang Jin-Qiang
• Marconi Jennifer Michelle

Classifications

• C12N2500/02

  Atmosphere, e.g. low oxygen conditions · CPC title

• A61K38/57

  from animals; from humans {(A61K38/553, A61K38/556 take precedence)} · CPC title

• A61K38/1841

  Transforming growth factor [TGF] · CPC title

• A61K38/39

  Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG] · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title